NDV-HXP-S 10μg

BIOLOGICAL2 trials

Sponsors

Butantan Institute

Conditions

Coronavirus InfectionsHealthy

Phase 1

Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil

CompletedNCT04993209

Butantan InstituteCoronavirus Infections, Healthy

Start: 2021-07-09End: 2022-11-04Updated: 2023-08-21

Phase 2

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

CompletedNCT05354024

Butantan InstituteCoronavirus Infections, Healthy

Start: 2023-02-28End: 2024-09-25Updated: 2025-02-06

Related Papers

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.

2025-03-031 citations

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

2023-05-1032 citations

Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.

2022-05-1431 citations

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

2022-03-0844 citations